

ASX Announcement (ASX: AXE)

31 March 2025

Archer enters partnership with Hylid Diagnostics for Biochip development

Highlights

- Archer has signed an agreement with Hylid Diagnostics to develop an at-home testing device for chronic kidney disease as part of the Biochip project.
- Archer and Hylid will combine their respective specialist blood sensing technologies to accelerate development and create a prototype system.
- Hylid specialise in medical devices for the at-home testing of blood samples as well as having a team of advisors to aid in the entry of regulatory processes and the setup of clinical trials.
- Archer and Hylid are now creating a detailed work plan for the next few months, including the first stage of the project which is to produce stand-alone hemolysis sensors that when used with Archer's Biochip will meet potassium measurement accuracy requirements.

Archer Materials Limited ("Archer", the "Company", "ASX: AXE"), a semiconductor company advancing the quantum technology and medical diagnostics industries, has signed an agreement with Canadian medical device company, Hylid Diagnostics Inc ("Hylid"), to develop the potassium measurement product for the testing of chronic kidney disease in its Biochip.

The partnership will involve Archer's Biochip team utilising its potassium sensing technology and Hylid's blood hemolysis sensor technology to develop a system that will meet the stringent accuracy requirements for blood potassium measurements. Together, the teams will combine hemolysis and potassium sensing technologies and then integrate into a prototype cartridge system.

Hylid specialises in using novel optical sensors to bring affordable, lab-quality blood testing to the home, with their first target market being chronic kidney disease in North America and Europe. Hylid have a team of advisors in the US, Canada, and UK to aid in the entry of regulatory processes for the relevant agencies and the setup of clinical trials.

The first stage of this joint project will be for Hylid to produce stand-alone hemolysis sensors that meet accuracy requirements and allow for the integration of Archer's potassium sensing chips with the aim of developing an at-home testing device. Then, Archer and Hylid will design and begin manufacturing an integrated cartridge system suitable for early-stage clinical testing and volume production.

Now that the agreement is in place, the respective company's engineering teams will be able to communicate freely to technically deep-dive and create a detailed work plan for the coming months.



Commenting on the partnership, Simon Ruffell, CEO of Archer, said,

"The team at Hylid and their technology align well with our goal of developing a Biosensor device for the at-home testing of chronic kidney disease.

"Hylid staff have significant industry experience in sensing, diagnostics, design, and manufacturing at leading companies such as Siemens and Alere (now Abbott). Hylid is also well-connected in key markets for Archer and the team looks forward to starting work with Hylid to create effective at-home testing of chronic kidney disease for improved patient outcomes."

The Board of Archer authorised this announcement to be given to ASX.

Investor enquiries

Media enquiries

Howard Marks +61 402 438 019 <u>howard.marks@automicgroup.com.au</u> Dylan Mark +61 475 783 675 dylan.mark@automicgroup.com.au

About Archer

Archer is a technology company that operates within the semiconductor industry. The Company is developing advanced semiconductor devices, including chips relevant to quantum computing, sensing, and medical diagnostics. Archer utilises its global partnerships to develop these technologies for potential deployment and use across multiple industries. <u>www.archerx.com.au</u>